How Much Do Ovulation Induction Drugs Cost in China? 2025 Price Reference & Cost Breakdown

Opening: Consultation Scene

A 32-year-old woman came to the clinic with her sex hormone panel and AMH report. She had been trying to conceive for one year and three months without success, had irregular menstrual cycles, and ultrasound suggested polycystic ovary morphology. She wanted to learn about ovulation induction treatment. Her first question after sitting down was, "Doctor, how much will the ovulation induction drugs cost? Will insurance cover it?" This question is asked almost daily in the reproductive clinic. Below, we break down the actual costs based on drug type, brand, protocol, hospital, and other dimensions.

Core Factors Influencing the Cost of Ovulation Induction Drugs

The cost of ovulation induction drugs is not a fixed number but is determined by the following six variables:

• Drug Type: Oral medications (Clomiphene, Letrozole) are the least expensive, injectable gonadotropins (HMG, FSH) are more expensive, and GnRH antagonists/agonists fall in between.
• Brand and Origin: Domestic brands cost about 40% to 60% of the price of imported brands, but the active ingredients and clinical outcomes have been proven equivalent in mainstream protocols.
• Treatment Protocol: Mild stimulation protocols use less medication and are less expensive; conventional antagonist protocols and long protocols have longer medication periods and higher total costs.
• Dosage and Duration: Dosage is individualized based on age, BMI, and ovarian reserve (AMH, antral follicle count). Higher doses and longer durations lead to higher costs.
• Hospital Level and Region: Public tertiary hospitals have lower drug markups, while some private fertility centers may have drug prices 10% to 25% higher.
• Medical Insurance Reimbursement Rate: Since 2024, many regions have included ovulation induction drugs in outpatient special disease categories or medical insurance coverage, but reimbursement rates and caps vary significantly.

Range of Ovulation Induction Drug Costs in China (2025 Reference)

Based on the factors above, the medication cost for a standard ovulation induction cycle is roughly as shown in the table below. The figures represent the median range of actual procurement prices from public tertiary hospitals across major provinces, serving as a budget reference for initial consultation patients.

Note: These are net drug costs, excluding injection fees, ultrasound monitoring fees, hormone testing fees, etc. Actual costs are subject to the hospital pharmacy's daily prices and may vary reasonably by manufacturer and specification.

Why Is There Such a Big Difference in Ovulation Induction Drug Costs?

The fundamental reason is that ovulation induction treatment is individualized; there is no "one-size-fits-all package."

• Different ovarian reserves require different dosages. A patient with AMH 1.2 ng/mL and one with AMH 0.4 ng/mL may have a starting dose of Gonal-f that differs by 75-150 IU/day, resulting in a 30%-50% difference in total medication.
• Protocol choice is determined by the cause. Patients with Polycystic Ovary Syndrome (PCOS) often use Letrozole + low-dose HMG, which has lower drug costs. In contrast, patients with Diminished Ovarian Reserve (DOR) require higher doses of FSH, naturally increasing costs.
• Brand premium comes from R&D and manufacturing. Imported recombinant FSH uses CHO cell expression systems, offering high purity and low batch-to-batch variability, but costs 1.8 to 2.5 times more than domestic counterparts. Domestic HMG and recombinant FSH have been used clinically for over twenty years, with ample evidence supporting their efficacy and safety.

How Do Reproductive Doctors Choose Ovulation Induction Drugs?

In clinical decision-making, doctors balance cost and effectiveness based on the following principles, rather than simply recommending the most expensive or cheapest drug:

• Prioritize efficacy and safety. For PCOS patients, Letrozole is the first-line ovulation induction drug due to its low cost, high monofollicular rate, and low risk of multiples and OHSS. For patients with normal ovarian function or low responders, recombinant FSH offers better follicular development uniformity.
• Domestic products as a first-line choice. Many reproductive centers in China now routinely use domestic HMG and domestic recombinant FSH as standard ovulation induction drugs. Clinical pregnancy rates show no statistical difference compared to imported products, but costs are reduced by about 40%.
• Dynamic adjustment based on treatment phase. During the mid-to-late follicular phase, if a premature LH surge or asynchronous follicular development occurs, adding a GnRH antagonist or adjusting the FSH dose may be necessary. This is contingency medication, making costs difficult to estimate precisely at the initial visit.
• Do not recommend reducing doses or shortening medication time to save money. The core goal of ovulation induction is to obtain an appropriate number of good-quality follicles. Insufficient medication may lead to cycle cancellation, ultimately increasing total time and financial costs.

Cost Differences Between Different Hospitals

In the same city, the price of the same ovulation induction drug can vary between hospitals. Differences mainly arise from the following three aspects:

• Public Tertiary A Hospitals vs. Private Fertility Centers: Public hospitals strictly implement a zero drug markup policy, with drug prices aligned with the provincial centralized drug procurement platform. Some private fertility centers charge drug management fees or cold chain service fees, leading to a 10%-20% increase in the price per vial.
• Different Pharmacy Procurement Channels: A few hospitals use a higher proportion of imported original drugs, resulting in higher overall drug costs. In contrast, hospitals primarily using domestic drugs can have total cycle costs 30%-40% lower.
• Package Pricing Models: Some private institutions offer "ovulation induction drug package prices." While the total price may appear lower on the surface, it is essential to confirm whether it covers all medications and any adjustments, to avoid "low-price引流, subsequent add-on fees."

It is recommended that after deciding on a treatment hospital, patients ask the pharmacy or doctor for a detailed medication order and cost breakdown, checking each item before collecting the medication. This is a patient's legitimate right and an effective way to avoid cost disputes.

4 Easily Overlooked Details in the Cost Breakdown

• Injection and Consumable Fees: Most ovulation induction drugs are administered subcutaneously or intramuscularly. The daily injection fee is about 10-30 RMB, accumulating to 300-900 RMB over a 30-day cycle. Some hospitals bundle injection fees into the treatment cost, while others charge them separately.
• Follicle Monitoring Fees: Each ovulation induction cycle requires 4-8 transvaginal ultrasounds and serum hormone tests (E2, LH, P). The cost per session is about 150-350 RMB, totaling 600-2800 RMB for the full cycle. This cost is often calculated separately from the medication fees.
• Cold Chain Storage and Transport for Medications: Recombinant FSH and GnRH antagonists require refrigeration at 2-8°C. If taking medication home from the hospital pharmacy, patients need to provide their own ice packs and cooling equipment. Some hospitals offer cold chain services but charge an additional fee.
• Medication Return Policy: During an ovulation induction cycle, the protocol may be adjusted due to poor or excessive ovarian response, potentially leaving some dispensed medication unused. Hospital policies on returning dispensed medication vary; some allow returns with a handling fee, while others do not accept returns. Be sure to understand the policy before collecting medication.

5 Common Misconceptions About Ovulation Induction Drug Costs

• Myth 1: Imported drugs are always better than domestic ones. For ovulation induction, domestic HMG and recombinant FSH show no significant difference in clinical pregnancy and live birth rates compared to imported products. The choice should primarily depend on the patient's financial situation and physical response, not a blind pursuit of imports.
• Myth 2: Buying drugs from unofficial channels saves money. Some patients purchase ovulation induction drugs through代购 or unauthorized online pharmacies, potentially saving 20%-30%. However, this carries risks of counterfeit drugs, loss of potency during transport, and lack of cold chain assurance, which can lead to cycle failure or even serious adverse reactions.
• Myth 3: Ovulation induction drug costs are fully covered by medical insurance. As of 2025, in most provinces, ovulation induction drugs fall under outpatient special disease categories or Class B drug coverage, with reimbursement rates between 40% and 70% and an annual cap (usually 2000-5000 RMB per year). They are not "fully covered"; expenses exceeding the cap must be paid out-of-pocket.
• Myth 4: Higher doses lead to higher success rates. Overusing ovulation induction drugs not only increases costs but also significantly raises the risk of Ovarian Hyperstimulation Syndrome (OHSS), potentially leading to cycle cancellation or delayed embryo transfer. The scientific approach is to use "enough to be effective."
• Myth 5: Drug prices are the same across all hospitals. As mentioned, due to differences in procurement channels, operating models, and pricing strategies, the price of the same drug can vary by more than 20% between hospitals. It is advisable to compare prices before paying.

Frequently Asked Questions from Patients

This article was written by a clinical reproductive medicine physician to provide objective and neutral cost reference information. It does not constitute any form of medical advice or commercial promotion. Please refer to your attending physician and the hospital pharmacy's actual information for specific medication plans and costs.